Bicycle Therapeutics plc (BCYC) Stock Forecast
BCYC analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.11 / 5 from 9 analysts
- Price target
- $9.50 average of analyst targets
- Upside to target
- +174.6% from the latest close
- Next earnings
- October 29, 2026 EPS estimate $-0.30
- 52-week range
- $3.38 – $8.76
BCYC analyst ratings
9 analystsNumber of analysts at each rating.
BCYC price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
BCYC earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.46 | −$0.65 | −$0.04 | −$0.85 | +46.0% | 8 |
| Current fiscal year (2026) | −$2.45 | −$2.80 | −$1.34 | −$3.16 | +22.4% | 8 |
| Next fiscal year (2027) | −$2.22 | −$2.87 | −$1.39 | −$2.45 | +9.4% | 8 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
BCYC revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $12.2M | $598,000 | $34.1M | +4.0% | 9 |
| Current fiscal year (2026) | $17.5M | $2.7M | $37.6M | −75.8% | 10 |
| Next fiscal year (2027) | $6.7M | $0 | $30.0M | −61.9% | 10 |
BCYC EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
BCYC revenue: reported and forecast
BCYC EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.50 | −$0.49 | −$0.49 | −$0.50 | −$0.46 | −8.1% | 2 up · 0 down |
| Current fiscal year (2026) | −$2.31 | −$2.27 | −$2.27 | −$2.61 | −$2.45 | +6.4% | 2 up · 1 down |
| Next fiscal year (2027) | −$2.13 | −$2.13 | −$2.13 | −$2.22 | −$2.22 | +4.2% | 0 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
BCYC earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; BCYC beat in 7 of 12.
What analysts expect from BCYC
9 analysts cover Bicycle Therapeutics; their consensus rating is buy (4.11 on a 1–5 scale, where 5 is a strong buy). The average price target is $9.50, 174.6% above the latest close of $3.46. Analysts expect earnings of −$2.45 per share for 2026, +22.4% from a year earlier. For 2027 the average estimate is −$2.22 per share on revenue of $6.7 million. Bicycle Therapeutics beat the EPS estimate in 7 of the last 12 quarters.
Related: BCYC income statement, BCYC key metrics, BCYC chart. See the BCYC stock overview for the latest quote and news.
BCYC forecast FAQ
What is Bicycle Therapeutics's price target?
The average analyst price target for Bicycle Therapeutics is $9.50, 174.6% above the latest close of $3.46.
Is Bicycle Therapeutics a buy, hold or sell?
Of 9 analysts covering Bicycle Therapeutics, 4 rate it a strong buy, 2 a buy, 3 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Bicycle Therapeutics's EPS forecast?
Analysts forecast −$2.45 per share for 2026 (range −$2.80 to −$1.34); for 2027 the estimate is −$2.22.
What is Bicycle Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $17.5 million, growth of −75.8%; for 2027 it is $6.7 million.
When does Bicycle Therapeutics report earnings?
Bicycle Therapeutics is expected to report results for the quarter ending September 30, 2026 on October 29, 2026 before the market opens; the EPS estimate is $-0.30.
Does Bicycle Therapeutics usually beat earnings estimates?
Bicycle Therapeutics reported EPS at or above the analyst estimate in 7 of the last 12 quarters.